A Hard Look: How Did China Pharma Growth Fall So Fast, So Steeply?
This article was originally published in PharmAsia News
While many are still shocked by the double-digit drop in quarterly pharma sales in the world’s second-largest economy, the underlying factors for the fast deterioration in China have in fact been brewing for some time and are multi-faceted, Yang Dongsheng of the R&D based Pharmaceutical Association Committee (RDPAC) tells PharmAsia News in an exclusive interview.
You may also be interested in...
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.
Covering nearly a third of the world’s population and roughly 30% of global GDP, the newly signed Regional Comprehensive Economic Partnership is set to accelerate trade within the Asia Pacific region. But India’s last-minute withdrawal means China may dominate the agenda going forward.